Genome-wide association studies have identified several risk associations for ovarian carcinomas but not for mucinous ovarian carcinomas (MOCs)
of ovarian carcinoma are among the best-defined genetic risk factors but explain only 10-15% of all ovarian cancers [6] [7] [8] . More recently, genome-wide association studies (GWAS) have identified multiple regions of the genome harboring common variants (minor allele frequency (MAF) > 0.05) conferring low risk (odds ratios (ORs) < 1.5) of invasive ovarian carcinoma [9] [10] [11] [12] [13] [14] [15] [16] [17] . However, it is increasingly recognized that ovarian carcinomas encompass multiple distinct disease histotypes 18 that vary in epidemiological [19] [20] [21] and genetic 22 risk factors, somatic alterations 23, 24 and clinical responses to platinumbased therapy 18 . Most of the known common risk alleles for ovarian carcinoma confer susceptibility to the most common histotype, high-grade serous ovarian cancer (HGSOC), with one genomic region also associated with the clear-cell histotype at genome-wide significance 12 . There are as yet no reports of confirmed genome-wide significant susceptibility loci for the other main histotypes, mucinous and endometrioid ovarian carcinomas.
MOCs are characterized by multicystic tumors with conspicuous amounts of intracellular mucin (usually present in ≥50% of the cytoplasm) in more than 90% of tumor cells 25 . Historically, MOCs have been estimated to account for about 12% of all ovarian carcinomas, but recent refinements in morphological assessment indicate that primary invasive MOCs comprise approximately 3% of all ovarian carcinomas 26 . This lower prevalence has several causes, including a consensus by pathologists to separate benign mucinous tumors from invasive MOCs 27 and pathology guidelines 26, [28] [29] [30] that aim to distinguish primary invasive MOCs from metastatic carcinomas involving the ovary, in which the majority of tumors derive from organs of the gastrointestinal system 26, 31 . These criteria, along with a frequent inability to find a non-ovarian primary cancer in affected individuals, suggest that true MOCs develop de novo at the ovary Genome-wide significant risk associations for mucinous ovarian carcinoma A full list of authors and affiliations appears at the end of the paper. and cannot be explained by metastatic lesions. The low incidence of MOCs has made it challenging to study the etiology and pathogenesis of these tumors.
At the genetic level, MOCs are not associated with germline BRCA1 or BRCA2 mutations. Unlike other ovarian carcinoma histotypes, invasive MOCs usually harbor foci of benign or atypical (low malignant potential (LMP)) epithelium, with identical KRAS mutations frequently present [32] [33] [34] , suggesting that these mutations are an early somatic event in a multistep progression model. Normal mucinsecreting cells are not present in the ovary, raising uncertainty regarding the cell type at risk of transformation. It has been hypothesized that some MOCs originate from foci of benign endocervical-subtype Müllerian metaplasia of the surface epithelium or cortical inclusion cysts 35 . This subtype, however, may be less frequently associated with fully invasive MOCs, which comprise mostly the intestinal subtype 35 . To further complicate the etiology of MOCs, expression analysis of small numbers of MOCs (n = 3-9) associated these tumors more closely with colonic epithelium or colorectal carcinomas (CRCs) than with ovarian surface epithelium 36, 37 , suggesting that pathogenesis in MOCs may be similar to that in CRCs 38 . The current study reports the identification of genetic susceptibility alleles for MOC, which may help to elucidate genes and biological pathways that are dysregulated during MOC development.
accuracy (Supplementary Note).
The primary association analyses reported here were based on Ovarian Cancer Association Consortium (OCAC)-Collaborative Oncology Gene-environment Study (COGS) participants of European ancestry and those with invasive or LMP MOC, comprising 1,644 cases (1,003 invasive and 641 LMP) and 21,693 controls ( Table 1) . We identified SNPs in three different regions that were associated with MOC at genome-wide significance (Fig. 1a-c and Table 2 ). Two of these regions (2q13 and 19q13.2) have not been previously associated with risk for ovarian carcinoma; the third region (2q31.1) has been reported to be associated with HGSOC 10 .
At 2q13, the most strongly associated SNP, rs752590, was imputed (imputation r 2 = 0.66, effect allele frequency (EAF) = 0.21). It is located 347 bases upstream of PAX8 (paired box 8), and the effect allele was associated with increased risk for all MOC (OR = 1.34, 95% confidence interval (CI) = 1.21-1.49; P = 3.3 × 10 −8 ) ( Table 2) . At 19q13.2, the most strongly associated SNP, rs688187, was also imputed (imputation r 2 = 0.55, EAF = 0.32). It lies approximately 489 kb downstream of IFNL3 (interferon, λ3), and the effect allele was associated with decreased risk for all MOC (OR = 0.67, 95% CI = 0.60-0.75; P = 6.8 × 10 −13 ). The risk was similar for invasive and LMP cases at both loci (data not shown). At 2q31.1, the most significantly associated SNP, rs711830 (EAF = 0.32), is located downstream of the 3′ region of HOXD3 (homeobox D3). The effect allele was associated with increased risk for all MOC (OR = 1.30, 95% CI = 1.20-1.40; P = 7.5 × 10 −12 ) ( Table 2) , with similar risks for invasive and LMP MOCs (data not shown). This SNP was also associated with invasive HGSOC (OR = 1.14; P = 1.9 × 10 −13 ) (Supplementary Table 3 ). It is highly correlated (r 2 = 0.99) with rs2072590, the variant previously reported for HGSOC 10 .
MOCs of extra-ovarian origin are more likely to be stage 3 tumors 26 . In our data set, only 146 of the 1,644 MOC cases (8.9%) were stage 3, suggesting that the majority of diagnoses in this study are likely to correspond to true primary ovarian MOCs. Risk estimates were also similar or larger (farther from the null hypothesis of no association) in women diagnosed with early-stage mucinous tumors in comparison to stage 3 tumors: OR = 1.39 (95% CI = 1.22-1.58; P = 5.4 × 10 −7 ) for rs752590 at 2q13; OR = 1.28 (95% CI = 1.17-1.41; P = 6.7 × 10 −8 ) for rs711830 at 2q31.1; and OR = 0.65 (95% CI = 0.56-0.75; P = 5.9 × 10 −9 ) for rs688187 at 19q13.2. These findings further support our initial findings.
Assessment of imputation quality
We assessed the imputation accuracy for the SNPs achieving genomewide significance by comparing the correlation of observed genotypes with estimated genotype doses from imputation without prephasing for 2,739 OCAC cases of European ancestry (Online Methods). We selected SNPs for genotyping on the basis of prephased imputation results. Where primer design failed and the original risk-associated SNP could not be genotyped, we selected a highly correlated (r 2 = 1) alternate SNP (Supplementary Table 4) . The correlation between the Table 3 ). We therefore compared the results of case-only analyses for 151 MOC cases and 2,588 cases with other invasive ovarian carcinoma histotypes using imputed genotype doses and observed genotypes (Supplementary Table 5 ). We confirmed the associations for the two alternate genotyped SNPs at 2q13, rs6542125 (case-only OR = 1.42, 95% CI = 1.07-1.90; P = 0.01) and rs6758928 (case-only OR = 1.41, 95% CI = 1.06-1.88; P = 0.02). Although the ORs from the genotyped samples were somewhat attenuated in comparison to that obtained with the imputed data, the P values were smaller, suggesting that the imputed association was robust. However, for rs35963157, there was no case-only association using imputed data in this subset of genotyped cases (case-only OR = 0.98, 95% CI = 0.69-1.39; P = 0.93). For the same samples, the association using observed genotypes was in the direction expected based on the full data set, although not significant (case-only OR = 0.88, 95% CI = 0.67-1.14; P = 0.33). The association was somewhat stronger when an additional 1,274 cases (59 MOC cases and 1,215 other ovarian carcinoma histotypes) without imputed data were included (case-only OR = 0.80, 95% CI = 0.64-1.00; P = 0.05), suggesting that the observed association for the imputed data is not due to artifacts of imputation.
Functional annotation of variants in risk regions
At each of the three risk-associated regions, we identified all SNPs with 1:100 or greater statistical odds of being the disease-causing variant (Supplementary Tables 6-8). We annotated these SNPs with respect to exons, introns and UTRs as well as the epigenetic marks from two ovarian epithelial cell lines and two ovarian carcinoma cell lines. Given the biological similarities between some MOCs and CRCs 40 , we also annotated these SNPs for the epigenetic marks profiled in a CRC cell line (HCT-116) and normal colonic tissues. The vast majority of the variants lay within noncoding DNA, suggesting that they influence the function of noncoding regulatory elements.
At 2q13, there were 55 candidate SNPs spanning a 78.6-kb region encompassing most of PAX8 and part of PSD4 (pleckstrin and Sec7 domain-containing 4) (Fig. 2) . Most risk-associated variants are in PAX8 introns, but the most statistically significant SNP (rs752590) and a moderately correlated variant (rs4849174, r 2 = 0.73) in an RNA polymerase II-binding site lie within the PAX8 promoter-proximal region. Three SNPs (rs874898, rs1478 and rs1479) lie within the 3′ UTR of PAX8 and so could influence RNA stability. Two SNPs (rs6734610 and rs7585510) lie within the sequence of the PAX8-AS1 long noncoding RNA (lncRNA) transcript (PAX8 antisense RNA 1) and so might affect its stability or function (Supplementary Table 8 ). Eleven (20%) and 13 (24%) SNPs were in enhancer elements detected in ovarian and colonic cells, respectively. Of these, rs2305132 was within a CTCF-binding site detected in multiple cell types, suggesting that this variant might be involved in the repression of PAX8 and/or PSD4 expression during MOC development.
At 19q13.2, there were 14 candidate SNPs located in and around IFNL3 and IFNL4 (Supplementary Table 8 ). rs11882871 lies within the 3′ UTR of IFNL3 and rs4803222 lies within the 5′ UTR of IFNL4, suggesting that they might influence RNA stability 41 . rs11322783 is a coding SNP and is predicted to cause a frameshift change in IFNL4, whereas rs8103142 encodes a missense change (lysine to arginine) in IFNL3. rs8103142 is predicted to be non-deleterious by PolyPhen-2 and SIFT. There were no overlaps between these 14 risk SNPs and regulatory DNA elements.
At 2q31.1, there were 19 candidate causal variants spanning ~27 kb encompassing HOXD3 and the lncRNA gene HAGLR (HOXD antisense growth-associated long noncoding RNA) ( Fig. 2  and Supplementary Table 8 ). There was extensive overlap between SNPs and regulatory elements in this region. Eleven and eight SNPs, respectively, coincided with putative enhancers in ovarian and colonic cells. rs1051929 encodes a synonymous change in HOXD3, and five SNPs lie within transcribed regions of the HAGLR and HAGLROS lncRNA genes.
eQTL analysis
We evaluated the associations between risk SNPs and transcript expression for all genes within a 100-kb window centered on the most strongly associated SNP in each region, using publicly available data for 339 HGSOCs and 121 CRCs from The Cancer Genome Atlas (TCGA) 42, 43 . No data were available for primary MOCs in TCGA. Where genotyping data were not available for a risk-associated SNP, correlated proxies (r 2 > 0.7) were evaluated. At 2q13, we detected a significant eQTL association between rs6542127, a variant highly correlated (r 2 > 0.9) with six risk-associated SNPs, and PAX8 expression in CRCs (P = 0.03, FDR = 0.09) (Fig. 3) . rs6542127 was associated with MOC risk (OR = 1.20; P = 8.81 × 10 −6 ). The most significant 
npg
A r t i c l e s eQTL association with PAX8 expression at this locus was for rs2863243 (P = 2.2 × 10 −6 ), but this SNP was not associated with MOC risk. However, the third most significant eQTL SNP (rs3748916, P = 3.1 × 10 −4 ) was associated with MOC risk (OR = 0.84; P = 9.37 × 10 −6 ). There were no statistically significant eQTL associations with PAX8 expression in HGSOCs. , there is extensive overlap between regulatory biofeatures and risk-associated SNPs. We also included collated Encyclopedia of DNA Elements (ENCODE) chromatin immunoprecipitation and sequencing (ChIP-seq) data for CTCF at 2q13; as PAX8 is rarely expressed in invasive MOCs, SNPs that coincide with repressor marks could be the most relevant for this disease subtype. FAIRE, formaldehyde-assisted isolation of regulatory elements; H3K27ac, acetylation of histone H3 at lysine 27; H3K4me1, monomethylation of histone H3 at lysine 4. (Fig. 3) . Another SNP in the region, rs10188827 (r 2 = 0.59 with rs711830), showed a slightly stronger eQTL association in HGSOCs (P = 2.05 × 10 −4 ) but a slightly weaker association with MOC risk (OR = 1.29, P = 3.41 × 10 −10 for all mucinous cases). There was also a stronger association between rs10188827 and HOXD9 expression in CRCs (P = 0.003), although the strongest eQTL association in CRCs was for another SNP, rs973456 (P = 5.30 × 10 −5 ), which had not been imputed. There were no eQTL associations for genes in the 19q13.2 region in either the HGSOC or CRC tumor data set.
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Functional characterization using in vitro models of MOC
The eQTL analyses in HGSOCs and CRCs suggested that HOXD9 is a candidate susceptibility gene and target of MOC risk-associated SNPs. We therefore evaluated the role of HOXD9 in MOC development. We used chromosome conformation capture (3C) to determine whether any of the risk SNPs at 2q31 interacted physically with the HOXD9 promoter in the MOC EFO-27 cell line. We found interactions for DNA fragments containing rs2072590, rs2857532 and rs4972504. These interactions spanned 31-55 kb of genomic DNA and were confirmed by sequencing (Fig. 4) . These genotyped variants are highly correlated with rs711830 (r 2 = 1, 0.98 and 0.89, respectively), the most significant risk-associated SNP in the region. Of the three SNPs, rs2072590 showed the greatest overlap with epigenetic marks, coinciding with enhancer marks in ovarian carcinoma cell lines, colon cancer cells and colonic crypts (Supplementary Table 8) . Taken together, the results from the eQTL and 3C analyses indicate that DNA regions at 2q31.1 harboring MOC risk SNPs are involved 
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in the regulation of HOXD9 expression. Future studies using genomeediting approaches to manipulate the different alleles of rs2072590 will be needed to evaluate effects on both regulatory activity and HOXD9 expression and to confirm the role of this SNP and HOXD9 in MOC development. We also evaluated the effects of overexpressing HOXD9 in two MOC cell lines (EFO-27 and GTFR230) using lentiviral transduction of a full-length HOXD9-GFP fusion construct. We confirmed overexpression of HOXD9 by quantitative PCR (qPCR) and immunofluorescence microscopy (Fig. 5) . We only detected HOXD9-GFP expression in the nucleus, whereas, in control cells expressing GFP only, we detected GFP signal throughout the cell. HOXD9 overexpression induced a significant increase in anchorage-independent growth in both MOC cell lines (P = 0.02 in EFO-27 cells and 0.04 in GTFR230 cells; Fig. 5) , indicating a role for HOXD9 in neoplastic transformation. We observed no effect on cellular invasion and migration (data not shown).
DISCUSSION
GWAS have identified common low-penetrance genetic susceptibility alleles for a multitude of common traits and diseases. As the size and scope of GWAS increase, so does the power to identify risk alleles for rare disease subtypes. For ovarian carcinomas, the vast majority of confirmed risk associations from GWAS were for HGSOCs, which account for almost two-thirds of all invasive ovarian carcinomas 24 . We report, for the first time to our knowledge, genome-wide significant risk associations for the rarer MOC histotype, identified as part of the largest genetic association study yet performed for ovarian carcinoma.
Two of the three susceptibility regions identified for MOC (2q13 and 19q13.2) are specific to this histotype, which may not be surprising given that MOCs are clinically and biologically distinct from other ovarian carcinoma histotypes. The third region associated with MOC risk (2q31.1) was previously reported as a susceptibility locus for HGSOC 10 . Similarly, the 17q12 risk region encompassing HNF1B was reported to be associated with HGSOC and the clear-cell ovarian carcinoma histotype 12 , suggesting that the different ovarian carcinoma histotypes have some degree of shared germline genetic etiology despite differences in somatic genetic alterations [22] [23] [24] , epidemiological risk factors [19] [20] [21] and responses to standard chemotherapy 18 . This overlap may reflect influences from the site of tumor development (the ovary) and the possible functional role of risk alleles interacting with common processes involved in malignancy, such as the ovarian microenvironment.
We identified PAX8 at 2q13 and HOXD9 at 2q31.1 as candidate MOC susceptibility genes using eQTL analysis of primary HGSOCs and CRCs. CRCs share some molecular and histological characteristics with MOCs 40 ; however, gene expression patterns and the functional mechanisms of risk-associated SNPs may be tissue specific 44 . We were unable to perform eQTL analyses in normal tissues or primary MOCs owing to the lack of publicly available data sets for this tumor histotype and uncertainty about the likely cell(s) of origin for it. Although the eQTL associations we identified were statistically significant, it is possible that eQTLs exist for MOC risk SNPs with other genes, either within these regions or regulated more distally. For example, at 2q13, we also observed regional associations of similar statistical significance to the association with PAX8 expression, including for PSD4 and a PAX8 antisense transcript, PAX8-AS1, although neither has previously been implicated in MOC development. We also found evidence of stronger eQTL associations for SNPs with weaker risk associations at both loci. In addition to effects from disease heterogeneity, eQTL analyses are complicated by intratumoral heterogeneity due to variation in copy number, methylation and gene expression. Thus, caution needs to be applied when interpreting eQTL data. Additional analyses in larger sample sizes and in tissues more relevant to MOC etiology will be needed to confirm the significance of HOXD9 and PAX8 as likely susceptibility genes for MOC at these loci.
Functional studies suggest that HOXD9 is the target MOC susceptibility gene at 2q31.1, demonstrating its interaction with three different regions harboring MOC risk-associated SNPs and its ability to enhance neoplastic phenotypes when overexpressed in MOC cells. HOXD9 is also a candidate susceptibility gene for HGSOC (K. Lawrenson, Q.L., S. Kar, J.-H.S., J.T. et al., unpublished data). The results from 3C analysis showed that one of the three HOXD9-interacting regions in MOC cells (containing rs4972404) also interacts with HOXD9 in HGSOC cells. This suggests that similar functional mechanisms regulating HOXD9 expression are acting in both MOCs and HGSOCs but that the other two interacting regions are tissue specific for MOCs, indicating the existence of regions that control regulation of HOXD9 in MOCs but not HGSOCs. HOXD9 is a member of the HOX family of transcription factors that are only expressed during embryonic development to control patterning and differentiation. HOXD9 has not been well characterized in the context of cancer development, although the gene was aberrantly expressed in cervical cancer 45 and has been implicated as a marker of cancer stem cells in glioma 46 .
The 2q13 MOC risk region has not previously been associated with risk of other diseases or traits. PAX8 is a plausible candidate susceptibility gene target at this locus. It encodes a transcription factor important in the development of the Müllerian duct 47 and may be a cell lineage marker that distinguishes carcinomas of gynecologic origin (for example, from the ovary, uterus, peritoneum or fallopian tube) from those originating at other sites, such as the gastrointestinal tract 23, 47, 48 . PAX8 is overexpressed in the majority of HGSOCs in comparison to normal ovarian epithelial cells 23 , partly as a result of gene amplification 49 , but is expressed in 10% (ref. 23 ) to 25% (L.E.K. and M. Kobel unpublished data) of LMP and invasive MOCs and is not expressed in CRC cell lines 49 . Although the precise role of PAX8 in cancer development is unclear, PAX8 expression may be important in acquiring characteristics that maintain a malignant state, including repression of differentiation programs for specific tissue lineages [49] [50] [51] .
The 19q13.2 risk region has been associated with impaired clearance of hepatitis C virus 52 and variation in response to hepatitis C virus therapy in Asians involving IFNL3 (also known as IL28B) 53 . The most likely functional risk SNP in this region is upstream of IFNL3 in the coding region of IFNL4: rs11322783 (also annotated as rs368234815 in dbSNP 141) is a predicted truncating variant, suggesting that it has a loss-of-function effect. The insertion allele turns IFNL4 into a polymorphic pseudogene and abolishes its activity 54 . The variant rs8103142 causes a nonsynonymous coding change (p.Arg70Lys) in IFNL3, but this change was predicted to be non-deleterious in vitro 55 . There are no reports implicating IFNL4 or IFNL3 specifically in the development of ovarian carcinoma or CRC, although multiple reports have indicated a role for interleukins more broadly in ovarian carcinoma. The 19q13 region has also been associated with structural rearrangements in ovarian carcinomas 56 .
The new risk associations we found at 2q13 and 19q13.2 were identified using imputed genotypes on the basis of estimated imputation r 2 values that were moderate for both SNPs. Imputation r 2 is an estimation of the expected correlation between imputed genotypes and actual genotypes. Confirmation genotyping of imputed SNPs in a subset of the samples showed that the estimated imputation correlation was similar to the correlation between imputed and observed npg A r t i c l e s genotypes. Furthermore, case-only associations for these SNPs based on observed genotypes had smaller P values, providing support for the imputed genotype associations. Although it is possible that imputation may be sensitive to small genotyping errors and differential with respect to case-control status, we would expect such biases to apply equally to all cases and not specifically to MOC cases. Because we did not observe significant associations with the other histotypes, the collective findings suggest that the associations with MOC are not due to biases in the imputation process.
The relatively large number of invasive and LMP MOCs in this study represents a major strength. We combined genotyping data from patients diagnosed with invasive or LMP MOC because these tumors are thought to evolve along a morphological continuum [32] [33] [34] . In the three susceptibility regions, the statistical significance of the risk associations was stronger in the combined analysis than in the LMP data set alone. However, molecular epidemiological studies are limited by access to details on clinical presentation and by the difficulty in performing centralized histological review. Although it is reasonable to assume that most LMP tumors arose primarily in the ovary, review of the histology and clinical records of the cancers might have led to exclusion of some cases that were metastases to the ovaries from non-ovarian primary cancers. To address this possibility, we evaluated risk associations for early-stage MOCs separately and observed similar or larger effect estimates. However, even when all the relevant clinical information is available and immunohistochemistry is performed, it is sometimes impossible to be certain of whether an MOC arose in the ovary or elsewhere 40 . Notably, we found no overlap between the risk associations we report for MOC and those discovered in GWAS of gastrointestinal cancers 57 , suggesting that the invasive MOCs in this study were mostly primary ovarian carcinomas rather than metastases.
In summary, we have reported the first genome-wide significant alleles to be identified for MOC. The power to detect risk associations for MOC has so far been limited by the small numbers of MOC cases collected through OCAC. The experiences of GWAS for more common cancers (for example, breast 58 and prostate 59 ) indicate that, with larger number of MOC cases, we would expect to identify additional susceptibility alleles for MOC. The functional evaluation that we performed for the MOC risk-associated regions also suggests that future studies are likely to provide new insights into understanding the biology of MOC. Finally, because MOC and HGSOC are distinct ovarian carcinoma histotypes and can be considered separate diseases 23, 24 , the identification of HOXD9 as a potential gene target showing oncogenic characteristics in both MOC and HGSOC can be considered independent evidence for the general role of this gene in oncogenesis. 
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